Dr. Anton Mamin has recently started his new position being responsible for strategic guidance to clinical trial growth and worldwide patient recruitment for epidemiological studies CENTOGENE is conducting. The main focus of CENTOGENE´s clinical trials is the validation and prospective monitoring of innovative and newly developed biomarkers in rare hereditary diseases.
Dr. Mamin said "I am thrilled to contribute to the fascinating development in the field of new biomarkers supporting a broad spectrum of clinical decisions in patients with rare genetic diseases. CENTOGNE is the perfect environment for me to further develop my international expertise".
Dr. Anton Mamin is an experienced clinical development executive, with a career spanning clinical monitoring, international project management (phases I-IIa-III including FiH studies) and most latterly supervising clinical operation in Central and Eastern Europe as Senior Director Clinical Operations and Director of Project Management Early phase Business Unit within global CRO. He completed his education at the Biophysical Department of the Saint Petersburg State Technical University with a Master of Science, and received his PhD in Biological Sciences at Institute of Cytology RAS followed by Postgraduate Research work at Leuven Medical University, in Belgium.
“The expansion of clinical trial opportunities is a priority at CENTOGENE. We welcome Anton´s experience as a leader in clinical trial development as we continue to expand our industry collaborations to support the patients suffering rare hereditary diseases” stated Prof. Rolfs, CEO CENTOGENE.